Video Series

Panelists discuss how immunoglobulin A (IgA) nephropathy represents a complex glomerular disease characterized by IgA deposition in the mesangium, with a wide spectrum of clinical presentations ranging from benign hematuria to progressive kidney failure requiring comprehensive management strategies.

A panelist discusses how new data from the 2025 American Academy of Dermatology Annual Meeting (AAD 2025) demonstrates tildrakizumab’s efficacy in treating nail psoriasis, with the 100-mg dose showing significant improvements in mNAPSI 75 and ViSENPsO responses at week 28 compared with placebo, potentially addressing a critical unmet need in psoriasis treatment.

Experts discuss the evidence supporting the continuous relationship between lipoprotein(a) (Lp[a]) levels and atherosclerotic cardiovascular disease (ASCVD), as recognized by the National Lipid Association, and explore how Lp(a) levels may change throughout a person’s lifetime or in response to lifestyle factors.

Experts discuss the relationship between lipoprotein(a) (Lp[a]) levels and atherosclerotic cardiovascular disease (ASCVD) risk, with findings from a large US population study, and explore how these findings could impact clinical practice and the management of patients at risk for ASCVD.

Experts discuss how institutions can develop standardized operational workflows that accommodate multiple bispecific products with different administration requirements, particularly as more products become available.

Experts discuss how the integration of continuous glucose monitoring (CGM) data into electronic health record (EHR) systems enhances clinical decision-making and care coordination, how primary care providers (PCPs) can leverage CGM data integration to provide more comprehensive diabetes care in the context of a shortage of endocrinologists, and the impact of varying coverage policies for CGM across different payers on patient access and outcomes, particularly for patients on basal insulin.

Panelists discuss how clinicians are addressing antimicrobial stewardship in urinary tract infection (UTI) management through implementation of evidence-based guidelines, delayed prescribing strategies, shorter treatment durations, targeted narrow-spectrum antibiotics based on local resistance patterns, increased use of culture-guided therapy, nonantibiotic preventive approaches, and enhanced patient education about appropriate antibiotic use.

Panelists discuss how health care institutions are leveraging strategic referral networks and telemedicine technologies to bridge geographical barriers, connect rural patients with specialized dementia care, establish hub-and-spoke models with community partners, and implement virtual cognitive assessments to dramatically improve both access and quality of care for patients with Alzheimer disease in underserved areas.

Panelists discuss how overcoming barriers to effective Alzheimer disease cognitive screening requires addressing multiple challenges including time constraints in clinical settings, inadequate reimbursement models, limited provider training, integration of screening tools into existing workflows, and patient concerns about diagnosis implications.

Experts discuss the role of continuous glucose monitoring (CGM)-derived metrics, particularly glucose management indicator (GMI), in the new Healthcare Effectiveness Data and Information Set (HEDIS) diabetes care measures and ACO quality targets, and how CGM-specific metrics are being incorporated into the National Committee for Quality Assurance (NCQA)’s quality measures and the implications for health plans.

A panelist discusses how clinicians should systematically adopt evidence-based hidradenitis suppurativa (HS) guidelines while maintaining flexibility to tailor treatments to individual patient needs, severity levels, and comorbidities. This involves regular monitoring of updated recommendations, implementing standardized assessment tools, and considering patient-specific factors such as lifestyle, preferences, and treatment response history to optimize therapeutic outcomes through a personalized medicine approach.

Experts discuss what partnerships between academic and community settings look like with regard to bispecifics, highlighting the role academic centers play in supporting community practices with bispecific therapy protocols.

Experts discuss key payer-related challenges, such as step edits and prior authorizations, that impact access to third-line therapies for patients with metastatic colorectal cancer (mCRC). They also discuss how payer requirements influence treatment sequencing and decision-making in the third-line setting and how the costs associated with adverse events across different third-line treatments affect treatment selection.

Experts discuss how pharmacists contribute to managing adverse events and toxicity for patients undergoing metastatic colorectal cancer (mCRC) treatment. They explore the factors influencing patient adherence to third-line therapies and ways pharmacists can improve patient education to enhance adherence to treatment regimens.

Experts discuss the clinical and economic burden of atherosclerotic cardiovascular disease (ASCVD) and aortic stenosis in the US, exploring their impact on health care systems, the importance of prevention in reducing this burden, and the challenges of implementing preventive strategies, while considering the potential benefits of improved risk assessment and prevention in the ASCVD space.

Experts discuss atherosclerotic cardiovascular disease and aortic stenosis, as well as their burden, highlighting their prevalence, impact on patient health, and the growing need for effective management strategies.

Panelists discuss how selecting an optimal combination of screening assessments for Alzheimer disease requires careful consideration of test sensitivity, specificity, accessibility, cost-effectiveness, implementation feasibility, and alignment with patient populations and health care resource constraints.

Panelists discuss how comprehensive patient education about proper hygiene practices, adequate hydration, voiding habits, and early symptom recognition significantly reduces urinary tract infection (UTI) incidence and recurrence rates, suggesting enhancement through personalized multimedia resources, telehealth follow-ups, community health programs, and improved provider-patient communication regarding preventive strategies.

Experts discuss the most common logistical challenges encountered when implementing bispecific therapies as well as the primary barriers smaller community practices face in operationalizing bispecific antibody treatments.

Experts discuss the relative value of different continuous glucose monitoring (CGM) metrics (glucose management indicator [GMI], time in range, glucose variability) in assessing glycemic control and how these outcomes vary across different patient populations.

Panelists discuss how significant knowledge gaps among nonspecialist providers—particularly regarding differential diagnosis, interpretation of cognitive assessments, and awareness of treatment options—are being addressed through targeted educational initiatives, embedded clinical decision support tools, and collaborative care models to enhance understanding of early Alzheimer diagnosis and treatment importance.

Experts discuss the clinical and practical factors that guide decision-making when recommending continuous glucose monitoring (CGM) vs traditional glucose monitoring for patients with type 2 diabetes.

Experts discuss the benefits of implementing and operationalizing bispecifics in the community oncology setting.

A panelist discusses how health system leaders should focus resources on implementing multidisciplinary care teams, standardizing staging/severity assessments, and ensuring access to recommended treatments outlined in current hidradenitis suppurativa (HS) guidelines. Priority areas include early diagnosis through provider education, establishing clear referral pathways to specialists, comprehensive symptom management including pain control, and tracking patient outcomes against quality metrics to improve care delivery and reduce disease burden.

Panelists discuss how uncomplicated urinary tract infection (UTI) recurrence affects 20% to 30% of female patients within 6 months of initial infection, with contributing factors including anatomical variances, hormonal changes, genetic predisposition, insufficient treatment duration, resistant pathogens, and biofilm formation that persists despite proper adherence to standard antibiotic protocols.

Experts discuss how the role of oncology pharmacists in managing metastatic colorectal cancer (mCRC) has evolved, particularly in enabling medication adjustments, refills, and prescribing supportive care medications, and explore the impact of this expanded role on patient outcomes and how pharmacists can leverage medication knowledge to optimize treatment and patient care further.

Experts discuss the typical patient journey for an individual with metastatic colorectal cancer (mCRC), highlighting where pharmacists participate in the process. They also explore how pharmacists collaborate with oncologists and other multidisciplinary team members to provide comprehensive care for patients with mCRC.

Panelists discuss how social determinants of health significantly influence uncomplicated urinary tract infection (UTI) prevalence and outcomes, with patients with lower income, those from rural areas, and those lacking consistent health care access experiencing higher infection rates, delayed treatment, increased complications, and poorer overall treatment success.